⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547314 | 1.00 | — | — | |
| SCHEMBL26606822 | 0.74 | KMO (0.42) | — | |
| SCHEMBL29518274 | 0.72 | — | — | |
| SCHEMBL22912663 | 0.72 | IDO1 (0.55) | — | |
| SCHEMBL810938 | 0.72 | CCR1 (0.48) | — | |
| SCHEMBL31484870 | 0.72 | CCR1 (0.48) | — | |
| SCHEMBL1697620 | 0.72 | — | — | |
| SCHEMBL4614 | 0.72 | — | — | |
| SCHEMBL29463643 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL1258340 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 756 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955498-A | Novel Tau protein-targeted PET imaging agent and preparation method thereof | 浙江大学 | 2024-11-15 | — | — | CN | claimed |
| CN-122080074-A | Tetradentate ring metal platinum (II) complex and organic electroluminescent device comprising same | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4294781-B1 | CATALYTIC METHOD FOR THE PREPARATION OF PERFLUOROALKOXY-SUBSTITUTED ARENES AND HETEROARENES | UNIV BERLIN FREIE (DE) | 2026-05-20 | — | — | EP | disclosed |
| CN-115650982-B | Compounds for imaging TAU protein aggregates | AC免疫有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260132139-A1 | HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125359-A1 | HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS | FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| WO-2026086812-A1 | INHIBITORS OF MENIN | RONGCHANG PHARMACEUTICALS, LTD. (CN) | 2026-04-30 | — | — | WO | disclosed |
| EP-1546133-A2 | N-SUBSTITUTE-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005028429-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1264826-B1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMA CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| US-6869966-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | MSD K.K. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1486497-A1 | NOVEL PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004031175-A2 | N-SUBSTITUTED-2-OXODIHYDROPYRIDINE DERIVATIVES AS NPY ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | WO | disclosed |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | MSD K.K. (JP) | 2004-04-15 | — | — | US | disclosed |
| US-20030158418-A1 | Novel imidazonline compounds | MSD K.K. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1264826-A1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |